×
About 14,420 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,084 results

Wound-Induced Hair Neogenesis Model.
https://doi.org/10.1016/j.jid.2022.07.013
The Journal of Investigative Dermatology; Xue Y, Lim CH et. al.

Sep 25th, 2022 - Skin wounds in adult mammals typically heal with a fibrotic scar and fail to restore ectodermal appendages, such as hair follicles or adipose tissue. Intriguingly, new hair follicles regenerate in the center of large full-thickness wounds of mice ...

An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adul...
https://doi.org/10.1182/blood.2022016862
Blood Izutsu K, Makita S et. al.

Sep 24th, 2022 - Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. We evaluated the efficacy and safety of valemetostat, a potent E...

Neurological post-acute sequelae of SARS-CoV-2 infection (PASC).
https://doi.org/10.1111/pcn.13481
Psychiatry and Clinical Neurosciences; Takao M, Ohira M

Sep 24th, 2022 - The novel corona virus infectious disease, COVID-19, caused by SARS-CoV-2, can have two phases: acute (generally 4 weeks after onset) and chronic (> 4 weeks after onset). Both phases include a wide variety of signs and symptoms including neurologi...

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Sep 23rd, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Natural History and Pathogenesis of Alopecia in Children and Adults
https://clinicaltrials.gov/ct2/show/NCT05502796

Sep 23rd, 2022 - Study Description: This is a study to detail the characteristics (genetic, immunologic, biological and demographic) of individuals who present in childhood and adulthood with alopecia and how alopecia impacts skin and systemic symptoms. Objectives...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  370 results see all →

Clinicaltrials.gov  439 results

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Sep 23rd, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Natural History and Pathogenesis of Alopecia in Children and Adults
https://clinicaltrials.gov/ct2/show/NCT05502796

Sep 23rd, 2022 - Study Description: This is a study to detail the characteristics (genetic, immunologic, biological and demographic) of individuals who present in childhood and adulthood with alopecia and how alopecia impacts skin and systemic symptoms. Objectives...

Long-Term PF-06651600 for the Treatment of Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04006457

Sep 23rd, 2022 - This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B793100...

Ritlecitinib for Cicatricial Alopecia
https://clinicaltrials.gov/ct2/show/NCT05549934

Sep 22nd, 2022 - Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial al...

Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04011020

Sep 22nd, 2022 - The SCE device is made of a hydrophobic material from FDA-approved (USP Class VI) dishes that tightly binds stem cells CB-SCs without interfering with their immune modulating capability. We originally designed a chamber for co-culture of lymphocyt...

see more →

News  860 results

Alopecia Areata: Positive Results Reported for Two Investigational JAK Inhibitors
https://www.medscape.com/viewarticle/981622

Sep 29th, 2022 - Treatment with deuruxolitinib and ritlecitinib, two investigational Janus kinase (JAK) inhibitors, resulted in substantial regrowth of scalp hair for patients with alopecia areata (AA) in separate studies reported at the European Academy of Dermat...

FDA Fast Tracks Approval of Novel Therapy for Rare Neurologic Disorder
https://www.medscape.com/viewarticle/981025

Sep 19th, 2022 - The US Food and Drug Administration (FDA) has granted accelerated approval to the novel gene therapy elivaldogene autotemcel (Skysona, bluebird bio) for the treatment of cerebral adrenoleukodystrophy (CALD). The therapy "is indicated to slow the p...

Low-dose oral minoxidil for the treatment of alopecia
https://www.mdedge.com/dermatology/article/257872/aesthetic-dermatology/low-dose-oral-minoxidil-treatment-alopecia
Lily Talakoub, MD

Sep 15th, 2022 - Therapeutic use of oral minoxidil in the treatment of androgenetic alopecia (AGA) is a lifeline for dermatologists who treat hair loss. Other than oral finasteride, vitamins, and topicals, there has been little advancement in the treatment of AGA.

Hormonal therapy a safe, long term option for older women with recalcitrant acne
https://www.mdedge.com/dermatology/article/257514/acne/hormonal-therapy-safe-long-term-option-older-women-recalcitrant-acne
Doug Brunk

Aug 31st, 2022 - PORTLAND, ORE. – During her dermatology residency training at the University of California, Irvine, Medical Center, Jenny Murase, MD, remembers hearing a colleague say that her most angry patients of the day were adult women with recalcitrant acne.

Oral paclitaxel+encequidar offers a possible alternative to IV paclitaxel in metastatic BC
https://www.mdedge.com/hematology-oncology/article/257214/breast-cancer/oral-paclitaxelencequidar-offers-possible

Aug 22nd, 2022 - Key clinical point: Patients with metastatic breast cancer (BC) who received oral paclitaxel plus encequidar to facilitate the absorption of oral paclitaxel showed higher confirmed tumor response compared with 3 weekly intravenous (IV) paclitaxel.

see more →

Patient Education  12 results see all →